Sentences with phrase «with infliximab»

Not exact matches

These results are aligned with previous infliximab antibody data among patients with inflammatory bowel diseases being treated with Remicade.

ew data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly - approved infliximab biosimilar CT - P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).

The study, published in the Inflammatory Bowel Disease Journal, evaluated the levels of infliximab, an antibody designed to bind to and block the effects of TNF - alpha, an inflammatory protein found in high levels in patients with IBD, such as Crohn's disease and ulcerative colitis, and numerous other inflammatory conditions such as rheumatoid arthritis and psoriasis.

In 2009, with that standard in mind, BIDMC attending physician Adam S. Cheifetz, MD began monitoring infliximab levels in his IBD patients with the goal of gradually adjusting their dosing regimens to hopefully improve long - term efficacy and decrease toxicity.

«Prolonging infliximab's efficacy and avoiding surgery and hospitalization is very important for patients with IBD,» said Cheifetz.

For this multicenter retrospective study, Cheifetz and colleagues analyzed the long - term outcomes of 264 patients with IBD on infliximab maintenance at either BIDMC or University of Pennsylvania hospitals, just under half of whom were monitored proactively.

The major players in the arthritis drug market include Remicade ® (infliximab), Humira ® (adalimumab), Enbrel ® (etanercept), Cimzia ® (certolizumab pegol) and Simponi ® (golimumab), while biosimilars of the above as well as new drugs with novel mechanisms of action are under development.

May 21, 2000 Study shows infliximab can maintain long - term remissions in Crohn's disease Periodic treatment with the monoclonal antibody infliximab can prolong remissions in patients with moderate to severe Crohn's disease.

In one recent trial, 9 a subset of patients resistant to antidepressant treatment and identified by serum markers of inflammation, most notably C - reactive protein > 3mg / L, were responsive to treatment with the TNF - alpha antagonist (anti-inflammatory) infliximab (Remicade).

Clicking thru to the main study you discuss, I noted a paragraph near the end that states that the semi-vegetarian diet is «effective for relapse prevention,» but that the authors» concern with «rapid, safe and reliable» induction of remission, which they say they achieve via infliximab.

Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment has been reported >

The researchers in the study found that 62 percent of depressed people with high blood levels of C - reactive protein had a reduction in their depression while taking the infliximab, while only 33 percent of those with normal CRP levels noted improvement.